SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Loefvenberg Eva)
 

Search: WFRF:(Loefvenberg Eva) > (2013) > A phase II study of...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

Andersen, Christen L. (author)
Dept Haematol, Roskilde Hosp, Roskilde, Denmark.; Dept Haematol, Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
McMullin, Mary F. (author)
Dept Haematol, Queens Univ Belfast, Antrim, North Ireland
Ejerblad, Elisabeth (author)
Uppsala universitet,Hematologi,Dept Haematol, Univ Uppsala Hosp, Uppsala, Sweden
show more...
Zweegman, Sonja (author)
Dept Haematol, Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
Harrison, Claire (author)
Dept Haematol, Guys & St Thomas Hosp, London, England; NHS Foundation Trust, London, England
Fernandes, Savio (author)
Bareford, David (author)
Dept Haematol, Russells Hall Hosp, Dudley, England
Knapper, Steven (author)
Dept Haematol, Cardiff Univ, Cardiff, S Glam, UK
Samuelsson, Jan (author)
Karolinska Institutet
Loefvenberg, Eva (author)
Haematol Ctr, Karolinska Univ Hosp, Stockholm, Sweden
Linder, Olle (author)
Andreasson, Bjorn (author)
Dept Haematol, NU Hosp Org, Uddevalla Hosp, Uddevalla, Sweden
Ahlstrand, Erik (author)
Region Örebro län
Jensen, Morten K. (author)
Dept Haematol, Herlev Hosp, Herlev, Denmark
Bjerrum, Ole W. (author)
Vestergaard, Hanne (author)
Dept Haematol, Odense Univ Hosp, Odense, Denmark
Larsen, Herdis (author)
Dept Internal Med, Dept Haematol, Viborg Hosp, Viborg, Denmark
Klausen, Tobias W. (author)
Mourits-Andersen, Torben (author)
Dept Haematol, Esbjerg Cent Hosp, Esbjerg, Denmark
Hasselbalch, Hans C. (author)
Dept Haematol, Roskilde Hosp, Roskilde, Denmark
show less...
Dept Haematol, Roskilde Hosp, Roskilde, Denmark; Dept Haematol, Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark Dept Haematol, Queens Univ Belfast, Antrim, North Ireland (creator_code:org_t)
2013-06-11
2013
English.
In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 162:4, s. 498-508
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat was followed by a decline in clonal myeloproliferation as defined by European Leukaemia Net. Thirty patients (48%) completed the intervention period (24 weeks of therapy). An intention-to-treat response rate of 35% was identified. Pruritus was resolved [19% to 0% (P=0.06)] and the prevalence of splenomegaly was lowered from 50% to 27% (P=0.03). Sixty-five per cent of the patients experienced a decrease in JAK2 V617F allele burden (P=0.006). Thirty-three patients (52% of patients) discontinued study drug before end of intervention due to adverse events (28 patients) or lack of response (5 patients). In conclusion, vorinostat showed effectiveness by normalizing elevated leucocyte and platelet counts, resolving pruritus and significantly reducing splenomegaly. However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Keyword

essential thrombocythaemia
polycythaemia vera
phase II study
histone deacetylase inhibition
vorinostat

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view